Plasma concentrations of asymmetric dimethylarginine, nitric oxide and homocysteine in patients with slow coronary flow

References

• Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, Dell'Italia LJ, Scibilia G, Motta P, Campa PP. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375–81.
   PubMedGoogle Scholar
• Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries – a new angiographic finding. Am Heart J 1972;84:66–71.
   PubMed Web of Science ®Google Scholar
• Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;74:964–72.
   PubMed Web of Science ®Google Scholar
• Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314–9.
   PubMed Web of Science ®Google Scholar
• Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:998–1005.
   PubMed Web of Science ®Google Scholar
• Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842–7.
   PubMed Web of Science ®Google Scholar
• Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, Marz W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273–83.
   PubMed Web of Science ®Google Scholar
• Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003;26:458–64.
   PubMed Web of Science ®Google Scholar
• Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542–4.
   PubMed Web of Science ®Google Scholar
• Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383–8.
   PubMedGoogle Scholar
• Gibson CM, Cannon CP, Daley WL, Dodge JT, Jr., Alexander B, Jr., Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879–88.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604–12.
   PubMed Web of Science ®Google Scholar
• Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493 e1–8.
   PubMed Web of Science ®Google Scholar
• Kucuktepe Z, Ozaydin M, Turker Y, Varol E, Erdogan D, Dogan A, Hicyilmaz H, Vural H. Izole koroner arter ektazisi olan hastalarda plazma asimetrik dimetil arginin duzeyleri [Asymmetric dimethylarginine levels in patients with isolated coronary ectasia]. SDU Tip Fak Derg [Med J SDU] 2010;17:19–25.
   Google Scholar
• von Leitner EC, Klinke A, Atzler D, Slocum JL, Lund N, Kielstein JT, Maas R, Schmidt-Haupt R, Pekarova M, Hellwinkel O, Tsikas D, D'Alecy LG, Lau D, Willems S, Kubala L, Ehmke H, Meinertz T, Blankenberg S, Schwedhelm E, Gadegbeku CA, Boger RH, Baldus S, Sydow K. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation201;124:2735–45.
   Google Scholar
• Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006;62:39–44.
   Google Scholar
• Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024–9.
   PubMed Web of Science ®Google Scholar
• Selcuk MT, Selcuk H, Temizhan A, Maden O, Ulupinar H, Baysal E, Ozeke O, Sasmaz A. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. Coron Artery Dis 2007;18:545–51.
   PubMed Web of Science ®Google Scholar
• Ari H, Ari S, Erdogan E, Tiryakioglu O, Huysal K, Koca V, Bozat T. The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyol Dern Ars 2010;38:327–33.
   PubMedGoogle Scholar
• Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005;10:S19–25.
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Schneider WR, Pokov A, Hetzel S, Demets D, Serebruany V, Schröder H. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010;15:344–8.
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141–6.
   PubMed Web of Science ®Google Scholar
• Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, Karakaya O. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J 2005;46:373–82.
   PubMed Web of Science ®Google Scholar
• Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–6.
   PubMed Web of Science ®Google Scholar
• Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation200;104:2569–75.
   Google Scholar
• Barutcu I, Sezgin AT, Sezgin N, Gullu H, Esen AM, Topal E, Ozdemir R. Elevated plasma homocysteine level in slow coronary flow. Int J Cardiol 2005;101:143–5.
   Google Scholar